Creatinine News and Research

RSS

High strength satin drugs do not increase risk of kidney injury among heart attack survivors

A higher strength of cholesterol-lowering drugs, or statins, did not increase the risk of kidney injury among heart attack survivors, according to preliminary research presented at the American Heart Association's Emerging Science Series Webinar.

20 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Vitamin C and gout: an interview with Prof. Lisa Stamp

A previous study in by Choi et al in the USA showed that people with a higher vitamin C intake have a lower risk of gout. There are also studies in healthy volunteers that suggest that vitamin C supplements reduce blood uric acid levels.

4 Jun 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013

Research reveals vitamin C does not reduce urate levels in gout patients

Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism.

17 May 2013

Organic pollutants increase nephropathy risk in diabetes

Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.

29 Apr 2013

Kidney disease screening needs rethink in hypertension

The standard approach to detecting chronic kidney disease fails to spot the condition in about a quarter of patients with hypertension, a study suggests.

29 Apr 2013

Nephropathy risk lowered by glucose, BP control in Type 1 diabetes

Individuals with Type 1 diabetes should keep good control of their blood sugar levels and blood pressure to reduce their risk for developing nephropathy, say researchers.

29 Apr 2013

Urine tests could improve diagnosis of liver cancer

New data from two clinical trials presented today at the International Liver Congress- 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests.

26 Apr 2013

Researchers report progress on non-invasive method to assess kidney function

Researchers may have found a way to block kidney-destroying inflammation and help damaged kidney cells recover.

17 Apr 2013

New study shows exposure to tobacco smoke could negatively impact adolescent kidney function

Exposure to tobacco smoke could negatively impact adolescent kidney function; this is according to a new study led by a team of researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Children's Center.

9 Apr 2013

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Bristol-Myers Squibb Company announced today that 14 abstracts on the Company's research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver, in Amsterdam, April 24 - 28.

8 Apr 2013

Researchers find association between melatonin, type 2 diabetes

With previous evidence suggesting that melatonin may have a role in glucose metabolism, researchers have found an independent association between decreased secretion of melatonin and an increased risk for the development of type 2 diabetes, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Cytori receives patent for methods of treating renal diseases using ADRCs

Cytori Therapeutics received US Patent No. 8,404,229 (the '229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs).

30 Mar 2013

Studies show protein semaphorin 3A helps detect acute kidney injury

A guidance cue that helps kidneys form may also be a red flag that they are in danger, researchers report.

13 Mar 2013

High-dose rosuvastatin reduces acute kidney injury caused by imaging dye in ACS patients

High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

12 Mar 2013

Urinary cystatin C prognostic marker in acute kidney injury

Urinary cystatin C level may be a useful biomarker for discriminating between prerenal and intrinsic acute kidney injury, report researchers.

1 Mar 2013

FDA committee recommends approval of Guerbet’s Dotarem NDA for adults and children

Guerbet, the contrast agent specialist for medical imaging, today announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older.

15 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

eGFR ‘powerful’ operative risk gauge

Patients’ estimated glomerular filtration rate is highly predictive of their risk for dying after surgery, shows a systematic review and meta-analysis.

8 Feb 2013